Sugi Predict

Sugi Predict / Compounds / SCHEMBL3098232

SCHEMBL3098232

SCHEMBL3098232

CCCCCC(CCC)CCCCCC[O]

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.50
▸ GPR84 Q9NQS5 5/20 0.40
▸ FDPS P14324 3/20 0.40
▸ FFAR1 O14842 1/20 0.40
▸ MAPT P10636 1/20 0.39
▸ LCK P06239 1/20 0.39
▸ PPARD Q03181 1/20 0.39
▸ ZDHHC20 Q5W0Z9 1/20 0.39
▸ ZDHHC2 Q9UIJ5 1/20 0.39
▸ DNM1 Q05193 1/20 0.39
▸ TSHR P16473 1/20 0.38
▸ THRB P10828 1/20 0.38
▸ ADH1B P00325 1/20 0.38
▸ ADH1C P00326 1/20 0.38
▸ ADH1A P07327 1/20 0.38
▸ ADH4 P08319 1/20 0.38
▸ ADH7 P40394 1/20 0.38
▸ LAP3 P28838 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3088607 1.00 LMNA (0.50) LMNAGPR84FDPSFFAR1MAPT
SCHEMBL3090809 1.00 LMNA (0.50) LMNAGPR84FDPSFFAR1MAPT
SCHEMBL3097309 0.95 LMNA (0.50) LMNAGPR84FDPSFFAR1MAPT
SCHEMBL3098081 0.95 LMNA (0.50) LMNAGPR84FDPSFFAR1MAPT
SCHEMBL3088606 0.95 LMNA (0.54) LMNAGPR84FDPSFFAR1MAPT
SCHEMBL27813253 0.95 LMNA (0.54) LMNAGPR84FDPSFFAR1MAPT
SCHEMBL3090859 0.93 ALDH1A1 (0.41) LMNAFDPSDNM1TSHR
SCHEMBL18429772 0.93 LMNA (0.50) LMNAGPR84FDPSFFAR1MAPT
SCHEMBL3100387 0.91 LMNA (0.50) LMNAGPR84FDPSFFAR1MAPT
SCHEMBL28669510 0.90 LMNA (0.54) LMNAGPR84FDPSFFAR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100279963-A1 DICARBONYL DERIVATIVES AND METHODS OF USE ABRAXIS BIOSCIENCE, LLC (US) 2010-11-04 — — US disclosed
US-7799954-B2 Dicarbonyl derivatives and methods of use ABRAXIS BIOSCIENCE, LLC (US) 2010-09-21 — — US disclosed
US-7674816-B2 Substituted melatonin derivatives, process for their preparation, and methods of use ABRAXIS BIOSCIENCE, LLC (US) 2010-03-09 — — US disclosed
EP-2125694-A2 DICARBONYL DERIVATIVES AND METHODS OF USE Abraxis BioScience, Inc. (US) 2009-12-02 — — EP disclosed
EP-1701718-A4 SUBSTITUTED MELATONIN DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE ABRAXIS BIOSCIENCE LLC (US) 2009-06-24 — — EP disclosed
EP-1976505-A1 COMBRETASTATIN DERIVATIVES AND RELATED THERAPEUTIC METHODS Abraxis BioScience, Inc. (US) 2008-10-08 — — EP disclosed
US-20080146586-A1 DICARBONYL DERIVATIVES AND METHODS OF USE ABRAXIS BIOSCIENCE (US) 2008-06-19 — — US disclosed
WO-2008064060-A2 DICARBONYL DERIVATIVES AND METHODS OF USE ABRAXIS BIOSCIENCE, INC. (US) 2008-05-29 — — WO disclosed
US-20070191463-A1 Substituted melatonin derivatives, process for their preparation, and methods of use ABRAXIS BIOSCIENCE, INC. (CA) 2007-08-16 — — US disclosed
WO-2007059118-A1 COMBRETASTATIN DERIVATIVES AND RELATED THERAPEUTIC METHODS ABRAXIS BIOSCIENCE, INC. (US) 2007-05-24 — — WO disclosed
EP-0460950-B1 Radicicol derivatives, their preparation and their anti-tumour activity SANKYO CO (JP) 1997-03-05 — — EP disclosed
US-5597846-A ESTERS OF RADICICOL SANKYO COMPANY, LIMITED (JP) 1997-01-28 — — US disclosed
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 — — US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 — — US disclosed
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 — — EP disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 — — US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 — — US disclosed
WO-1991018905-A1 RADICICOL DERIVATIVES, THEIR PREPARATION AND THEIR ANTI-TUMOR ACTIVITY SANKYO COMPANY LIMITED (JP) 1991-12-12 — — WO disclosed
EP-0460950-A1 Radicicol derivatives, their preparation and their anti-tumour activity Sankyo Company Limited (JP) 1991-12-11 — — EP disclosed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146586-A1 DICARBONYL DERIVATIVES AND METHODS OF USE AADAC, DCK, MLYCD LMNA 2382/4885GPR84 4579/4885FDPS 261/4885
US-20100279963-A1 DICARBONYL DERIVATIVES AND METHODS OF USE AADAC, DCK, MLYCD LMNA 2382/4885GPR84 4579/4885FDPS 261/4885
US-20070191463-A1 Substituted melatonin derivatives, process for their preparation, and methods of use MTNR1B, MTNR1A, CYP3A5 LMNA 1448/4885GPR84 800/4885FDPS 3789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.